Hemab Therapeutics (NASDAQ:COAG) Shares Up 6% – Time to Buy?

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shot up 6% on Thursday. The company traded as high as $30.65 and last traded at $30.43. 238,850 shares traded hands during trading, a decline of 36% from the average daily volume of 376,088 shares. The stock had previously closed at $28.70.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HC Wainwright raised their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Wedbush boosted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. Finally, Jefferies Financial Group boosted their price target on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Hemab Therapeutics Trading Up 5.4%

The business has a fifty day moving average of $43.34. The stock has a market capitalization of $1.41 billion and a PE ratio of -1.22.

Hemab Therapeutics (NASDAQ:COAG) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Hemab Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth $230,000. The Manufacturers Life Insurance Company bought a new position in shares of Hemab Therapeutics during the 2nd quarter worth about $688,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $1,750,000. State Street Corp acquired a new stake in Hemab Therapeutics during the second quarter worth about $2,825,000. Finally, Braidwell LP acquired a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.